NCT02009878View on ClinicalTrials.gov

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Interventions
DRUG

tolvaptan

Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1

Trial Locations (14)

1083

Semmelweis Egyetem AOK, Budapest

7500

Holstebro Regionhospital, Holstebro

13125

Evangelische Lungenklinik Berlin, Berlin

23538

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Lübeck

28040

Hospital Universitario Clinico San Carlos, Madrid

30167

Medizinische Klinik im Klinikum Hannover, Hanover

41345

Sahlgrenska Universitetssjukhuset, Gothenburg

50937

Universitaetsklinikum Koeln, Cologne

128 08

Vseobecna fakultni nemocnice V Praze, Prague

01307

Universitätsklinikum C.-G.-Carus, Dresden

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

B9 5SS

Birmingham Heartlands Hospital, Birmingham

NW3 2QG

Royal Free Hospital, London

M20 4BX

The Christie Hospital, Manchester

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT02009878 - A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) | Biotech Hunter | Biotech Hunter